XTL Biopharmaceuticals’ Lupus Drug Candidate Edratide Granted Patent in Hungary
Israel-based XTL Biopharmaceuticals, a clinical stage biotech company that focuses on the development of new drugs for the treatment of autoimmune diseases, has announced that its lead drug candidate, hCDR1, has been granted a patent by the Hungarian Intellectual Property Office. The patent, “Synthetic Human Peptides and Pharmaceutical Compositions Comprising…